BridgeBio Pharma, Inc. (BBIO) News
Filter BBIO News Items
BBIO News Results
|Loading, please wait...|
BBIO News Highlights
- For BBIO, its 30 day story count is now at 13.
- Over the past 28 days, the trend for BBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- GENE, CAH and BEAT are the most mentioned tickers in articles about BBIO.
Latest BBIO News From Around the Web
Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.
BridgeBio Pharma press release (BBIO): Q4 GAAP EPS of -$1.01 misses by $0.16.Revenue of $12.89M (+10641.7% Y/Y) misses by $8.69M.Shares -4.5% PM.
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data readout anticipated in second half of 2022 –Launched clinical collaboration with Amgen to study BBP-398, a potentially best-in-class SHP2 inhibitor, in combination with LUMAKRAS® (sotorasib) in advanced solid tumors with the KRAS G12C mutation –Es
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.
BridgeBio Pharma (BBIO) closed the most recent trading day at $8.54, moving -1.61% from the previous trading session.
Mizuho Securities analyst Salim Syed maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) today and set a price target of $25.00. The company's shares closed last Wednesday at $10.23, close to its 52-week low of $8.46. According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of -12.9% and a 37.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences. Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $27.20, which is a 176.7% upside from current levels.
BridgeBio Pharma (BBIO) closed the most recent trading day at $9.99, moving +1.83% from the previous trading session.
BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.
BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.